TickerFacts.

Sera Prognostics, Inc. (SERA): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

-$83.0K
Year ended 2025-12-31
-$105.0K
Trailing 12 months to 2026-06-30
$96.0K2023-12-31: $96.0K2024-12-31: -$5.0K2025-12-31: -$83.0K-$83.0K
2023-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31-$83.0Kn/m2026-03-18, From 2025-01-01
2024-12-31-$5.0Kn/m2026-03-18, From 2024-01-01
2023-12-31$96.0Kn/a2025-03-19, From 2023-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
Sera Prognostics, Inc. (SERA)2025-12-31-$83.0Kn/m
Aclarion, Inc. (ACON)2025-12-31$6.8Kn/m
YD Bio Ltd (YDES)2025-12-31$167.4K+7.8%
BioNexus Gene Lab Corp (BGLC)2025-12-31$1.09M-15.8%
American Shared Hospital Services (AMS)2025-12-31$5.06M-44.9%
Exagen Inc. (XGN)2025-12-31$38.80M+17.2%
Personalis, Inc. (PSNL)2025-12-31$15.78M-41.2%
BillionToOne, Inc. (BLLN)2025-12-31$208.46M+157.6%
Fulgent Genetics, Inc. (FLGT)2025-12-31$130.88M+22.1%

Compare SERA, ACON, YDES, BGLC side by side · Screen every company in Services-Medical Laboratories ↗